Antibodies targeting the interactions between ACE2 and SARS-CoV-2 Spike RBD efficiently neutralize SARS-CoV-2 infection and reduce viral load in animal models and COVID-19 patients (6, –, 10). The gene discussed is ACE2; the disease is COVID-19.